You are browsing articles on the topic of Heart Failure Archives - CardioExchange
The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a…
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.
In this scenario based on a patient’s question about the CardioMEMS device, John Ryan asks, “What do you say to your patient?”
Study Offers Little Support for an Old Drug (11 Aug 2014)
Digoxin is one of the oldest drugs in the cardiovascular arsenal, derived from the foxglove plant and first described in the 18th century by William Withering. It is frequently used in patients with heart failure (HF) and with atrial fibrillation (AF). The few trials supporting its use were performed in HF patients before newer treatments…
John Ryan interviews Dr. Ileana Piña about her work in HF-ACTION as it relates to the CMS’s recent expansion of cardiac rehabilitation coverage.
Colleen K. McIlvennan, Larry A. Allen, and Daniel D. Matlock discuss their study of how patients choose whether to get a left ventricular assist device as destination therapy.
The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure (HF). Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck)….
Actelion has announced positive top-line results for a phase III trial of a new oral drug for the treatment of pulmonary arterial hypertension (PAH). The drug, selexipag, is a first-in-class orally available selective prostacyclin IP receptor agonist. The pivotal, double-blind GRIPHON study was the largest outcome trial ever performed in PAH. A total of 1,156 PAH patients were randomized to selexipag or…